复发弥漫性大B细胞淋巴瘤血清血管内皮细胞生长因子的表达及其临床意义

Serum vascular endothelial growth factor in relapsed diffuse large B cell lymphoma and its clinical significance

目的探讨复发弥漫性大B细胞淋巴瘤(DLBCL)血清中血管内皮生长因子(VEGF)的表达及其临床意义。方法采用酶联免疫吸附法(ELISA)对23例复发DLBCL患者及23例正常体检者(对照组)进行血清VEGF测定。结果复发的DLBCL患者VEGF水平高于对照组(P<0.01);Ⅲ、Ⅳ期患者高于Ⅰ、Ⅱ期患者(P<0.01);GCB组VEGF水平高于N-GCB组(P<0.01)。ESHAP+利妥昔单抗+自体干细胞移植(ASCT)组经治疗后患者血清VEGF水平下降至正常或接近正常,与治疗前比较,差异有统计学意义(P<0.01)。结论血清VEGF可作为复发DLBCL的一种监测指标,反映复发DLBCL的疾病状态,对判断病情、预测复发、指导治疗具有一定临床意义。

Objective To investigate the levels of serum vascular endothelial growth factor（VEGF） in relapsed diffuse large B cell lymphoma（DLBCL）,and their clinical significance.Methods Enzyme-linked immunosorbent assay（ELISA） was used to measure serum VEGF levels in 23 patients with relapsed DLBCL and 23 normal subjects（control group）.Results Serum VEGF levels were significantly higher in patients with relapsed DLBCL than those in controls（P0.01）;and those in stage Ⅲ and Ⅳ were higher than those of stage Ⅰand Ⅱ（P0.01）.Serum VEGF levels in DLBCL of subtype GCB were higher than those of subtype NGCB（P0.01）.Serum VEGF levels decreased to normal or approached to normal in DLBCL patients receiving ESHAP ＋ Rituximab ＋ autologous stem cell transplantation（ASCT） after treatment（P0.01）.Conclusion Serum VEGF can be used as a monitoring indicator for the disease state and therapeutic responses of relapsed DLBCL.